Комплексная клинико-экономическая оценка применения антимикробных препаратов на стационарном этапе оказания медицинской помощи



Pdf просмотр
страница147/147
Дата03.03.2020
Размер2.63 Mb.
1   ...   139   140   141   142   143   144   145   146   147
Clostridium
difficile- ассоциированной диареи [Электронный документ]. – Режим доступа: http://www.gnck.ru/rec/recommendation_clostridium_difficile.pdf
34. Козлов, Р.С. Стратегия использования антимикробных препаратов как попытка ренессанса антибиотиков / Р.С. Козлов, А.В. Голубев // Клин. Микробиол.
Антимикроб. Химиотер. – 2011. –Т. 3, № 4. – С. 322-334.
35. Колбин, А.С. Основные понятия в оценке медицинских технологий: метод.
Пособие / А.С. Колбин, С.К. Зырянов, Д.Ю. Белоусов. – М.: Издательство ОКИ,
2013. – 42 с.
36. Колясникова, Н.М. Социально-экономическое бремя клещевого энцефалита в
Российской Федерации / Н.М. Колясникова, Н.А. Авксентьев, М.В.
Авксентьева // Медицинские технологии. Оценка и выбор. – 2013. – Т. 3, № 13.
– С. 44-55.
37. Кузьменков,
А.Ю.
AMRmap:
Интернет-платформа мониторинга антибиотикорезистентности / А.Ю. Кузьменков, И.В. Трушин, А.А. Авраменко
// Клин. Микробиол. Антимикроб. Химиотер. – 2017. – Т.19, № 2 – С. 84-9.
38. Куликов, А.Ю. Определение порога «готовности платить» при одобрении медицинских технологий в условиях российского здравоохранения, рассчитанного на основе паритета покупательной способности / А.Ю. Куликов,
Д.Т. Угрехелидзе, Р.И. Ягудина // Фармакоэкономика. – 2015. – Т. 3, № 3. – С.
5-9.
39. Лобзин, Ю.В. Клинические рекомендации по оптимизации антибактериальной терапии в медицинских учреждениях Санкт-Петербурга / Ю.В. Лобзин, С.В.
Сидоренко, А.С. Колбин – ООО «БМН», 2017. – 36 с.
40. Маждраков, Г. Болезни почек / Г. Маждраков, Н. Попов. - София: Медицина и физкультура, 1976. – 80 c.


248

41. Омельяновский, В.В. Анализ стоимости болезни — проблемы и пути решения
/ В.В. Омельяновский, М.В. Авксентьева, Е.В. Деркач // Педиатр. фармакология. - 2011. – Т. 8, № 3. - С.6-12.
42. Омельяновский, В.В. Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата
[Электронный ресурс] / В.В. Омельяновский, М.В. Авксентьева, М.В. Сура. –
Режим доступа: https://rosmedex.ru/hta/recom/.
43. Омельяновский, В.В. Методические рекомендации по расчету затрат при проведении клинико-экономических исследований лекарственных препаратов
[Электронный ресурс] / В.В. Омельяновский, М.В. Авксентьева, М.В. Сура. –
Режим доступа: https://rosmedex.ru/hta/recom/.
44. Омельяновский, В.В. Методические рекомендации по проведению мета- анализа [Электронный ресурс] / В.В. Омельяновский, М.В. Авксентьева, М.В.
Сура. – Режим доступа: https://rosmedex.ru/hta/recom/.
45. Омельяновский, В.В. Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи [Электронный ресурс]
/ В.В. Омельяновский, М.В. Авксентьева, М.В. Сура. – Режим доступа: https://rosmedex.ru/hta/recom/.
46. Осадчук, М.А., Свистунов А.А. Антибиотик-ассоциированная диарея в клинической практике / М.А. Осадчук, А.А. Свистунов // Вопр. соврем. педиатрии. – 2014. – Т. 13, № 1. – С. 102-108.
47. Основные итоги работы в сфере здравоохранения Санкт-Петербурга в 2018 году и основные задачи на 2019 год. – СПб.: СПБ ГБУЗ МИАЦ, 2019. – 56 с.
48. Палагин,
И.С.
Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010–2011) / И.С. Палагин, М.В. Сухорукова, А.В.
Дехнич // Клин. Микробиол. Антимикроб. Химиотер. – 2012. – Т. 14, № 4. – С.
280-302.


249

49. Платонов, А.Е. Социально-экономическое бремя пяти природно-очаговых инфекций в Росиийской Федерации / А.Е. Платонов, Н.А. Авксентьев, М.В.
Авксентьева // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. – 2015. – Т. 8, № 1. – С. 47-56.
50. Постановление Главного государственного санитарного врача РФ от 18 мая
2010 года №58 «Об утверждении СанПиН 2.1.3.2620-10 «Санитарно- эпидемиологические требования к организациям, осуществляющим медицинскую деятельность» [Электронный документ]. - Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_104071/.
51. Постановление Правительства РФ от 04.12.2014 г. №1316 «О предельной величине базы для начисления страховых взносов, уплачиваемых в Фонд социального страхования Российской Федерации и в Пенсионный фонд
Российской Федерации, с 1 января 2015 года» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_171922/.
52. Постановление Правительства РФ от 28.08.2014 №871 (ред. от 12.06.2017) «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи» [Электронный ресурс].

Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_167999/.
53. Прейскурант платных услуг (работ), оказываемых ФБУЗ «Центр гигиены и эпидемиологии в городе Санкт-Петербург» и его Филиалами на 05.07.2018 года
[Электронный ресурс]. – Режим доступа: https://78centr.ru/.
54. Прейскурант цен на оказание платных медицинских услуг НИИ СП. – 2017
[Электронный ресурс].

Режим доступа: http://www.emergency.spb.ru/services/paid/328-price.
55. Приказ Министерства здравоохранения Российской Федерации от 7 ноября
2012 г. №657н «Об утверждении стандарта специализированной медицинской помощи при острой респираторной вирусной инфекции тяжелой степени тяжести»
[Электронный ресурс].

Режим доступа:


250
http://www.consultant.ru/document/cons_doc_LAW_142316/2ff7a8c72de3994f304 96a0ccbb1ddafdaddf518/.
56. Приказ Минэкономразвития России №192, Минздравсоцразвития России
№323н, Минфина России №45н, Росстата №113 от 10.04.2012 «Об утверждении
Методологии расчета экономических потерь от смертности, заболеваемости и инвалидизации населения» (Зарегистрировано в Минюсте России 28.04.2012 № 23983)
[Электронный ресурс].

Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_129302/.
57. Приказ Минздравсоцразвития России от 26.08.2010 №575н «Об утверждении порядка осуществления мониторинга безопасности лекарственных препаратов для медицинского применения, регистрации побочных действий, серьезных нежелательных реакций, непредвиденных нежелательных реакций при применении лекарственных препаратов для медицинского применения»
[Электронный ресурс].

Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_104356/.
58. Принципы организации периоперационной антибиотикопрофилактики в учреждениях здравоохранения. Федеральные клинические рекомендации – М.
2014. – 42 с.
59. Проект клинических рекомендаций «Внегоспитальная пневмония», 2018
[Электронный ресурс].

Режим доступа: http://www.antibiotic.ru/files/pdf/2018/vp2018-project.pdf.
60. Распоряжение Комитета по Здравоохранению Администрации Санкт-
Петербурга от 20.07.2015 №292-р «О регламенте взаимодействия участников мониторинга распространения резистентных к антимикробным препаратам возбудителей госпитальных инфекций в Санкт-Петербурге» [Электронный ресурс].

Режим доступа: http://spbmiac.ru/wp- content/uploads/2017/12/Predvaritelnye-rezultaty-vnedreniya-Rasporyazheniya-
Komiteta-po-zdravoohraneniyu-Sankt-Peterburga-ot-20.07.2015-292-r_Zueva-
L.P.pdf.


251

61. Рафальский, В.В. Резистентность возбудителей амбулаторных инфекций мочевыводящих путей по данным многоцентровых микробиологических исследований UTIAP-I и UTIAP-II / В.В. Рафальский, Л.С. Страчунский, О.И.
Кречикова // Урология. – 2004. - № 2. – C. 13-17.
62. Российские клинические рекомендации [Электронный ресурс]. – Режим доступа: http://cr.rosminzdrav.ru/#!/.
63. Российские клинические рекомендации. Программа СКАТ (Стратегия контроля антимикробной терапии) при оказании стационарной медицинской помощи
[Электронный ресурс].

Режим доступа: http://nasci.ru/_resources/directory/313/common/Skat2018.pdf.
64. Савельев В.С. Стратегия и тактика применения антимикробных препаратов в стационарах России. Национальные клинические рекомендации [Электронный ресурс] / Под ред. Савельева В.С., Гельфанда Б.Р., Яковлева С.В. – М. 2012. –
Режим доступа: http://www.volgmed.ru/uploads/files/2013-3/17552- strategiya_i_taktika_primeneniya_antimikrobnyh_sredstv_v_lechebnyh_uchrezhde niyah_rossii_rossijskie_nacionalnye_rekomendacii_2012_http_sia-r_ru.pdf.
65. Савельев, В.С. Абдоминальная хирургическая инфекция. Национальные рекомендации / В.С. Савельев, Б.Р. Гельфанд. - М.: Боргес, 2011. – 98 с.
66. Савельев, В.С. Перитонит / В.С. Савельев, Б.Р. Гельфанд, М.И. Филимонов. -
М: Литтерра, 2006. – 206 с.
67. Самсонов, А.А. Антибиотики: друзья или враги, как найти консенсус? Взгляд гастроэнтеролога на антибиотик-ассоциированную диарею / А.А. Самсонов,
Е.Ю. Плотникова, А.А. Самсонов // Трудный пациент. – 2012. - № 6. – С. 16-24.
68. Сидоренко, С.В. Фармакоэпидемиологическое исследование использования антибактериальных средств в многопрофильных стационарах Санкт-
Петербурга / С.В. Сидоренко, А.С. Колбин, С.А. Шляпников // Антибиотики и химиотерапия. – 2017. – № 62. – С. 17-22.
69. СНиП II-Л.9-70 Больницы и поликлиники. Нормы проектирования.
Утверждены Государственным комитетом Совета Министров СССР по делам


252
строительства 31 декабря 1970 г. [Электронный ресурс]. – Режим доступа: http://docs.cntd.ru/document/1200065278.
70. Социально-демографический портрет России: По итогам Всероссийской переписи населения 2010 года. Федер. служба гос. статистики. – М.: ИИЦ
«Статистика России», 2012. – 183 с.
71. Стандарты специализированной медицинской помощи [Электронный ресурс].

Режим доступа: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-
979/stranitsa-983/2-standarty-spetsializirovannoy-meditsinskoy-pomoschi.
72. Сурков, Д.Н. Эпидемиология неонатального сепсиса: анализ работы отделения интенсивной терапии для новорожденных / Д.Н. Сурков, А.Д. Суркова, Д.О.
Иванов // Вестн. современной клин. медицины. – 2014. – Т. 7, № 6. – С.56-61.
73. Федеральная служба государственной статистики. Официальный сайт
[Электронный ресурс]. – Режим доступа: www.gks.ru.
74. Федеральный закон от 29.12.2006 №255-ФЗ (ред. от 03.12.2011) «Об обязательном социальном страховании на случай временной нетрудоспособности и в связи с материнством» [Электронный ресурс]. – Режим доступа: http://www.consultant.ru/document/cons_doc_LAW_64871/.
75. Фокин, А.А. Уроки эпидемиологических исследований нозокомиальных инфекций в России / А.А. Фокин // Клин. Микробиол. Антимикроб. Химиотер.
– 2008. – Т. 10, № 8. - С. 4-14.
76. Фролов, М.Ю. Методика проведения ABC/VEN-анализа / М.Ю. Фролов, О.Н.
Барканова, О.В. Шаталова // Лекарственный вестн. – 2012. – Т. 6, № 6. – С. 3-6 77. Чучалин, А.Г. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Российское респираторное общество, МАКМАХ. – 2014 г. / А.Г. Чучалин, А.И.
Синопальников, Р.С. Козлов – Режим доступа: http://www.pulmonology.ru/.
78. Эпидемиология и эпидемиологический мониторинг инфекций, вызванных метициллинрезистентными штаммами золотистого стафилококка.
Федеральные клинические рекомендации. – М., 2014. – 50 с.


253

79. Ягудина, Р.И. Методология проведения анализа «затраты-полезность» при проведении фармакоэкономических исследований / Р.И. Ягудина, И.В.
Сороковиков // Фармакоэкономика. – 2012. – Т. 5, № 2. – C. 9-12.
80. Ягудина, Р.И. Экономическое бремя хронической болезни почек в Российской
Федерации / Р.И. Ягудина, В.Г. Серпик, Г.Т. Абдрашитова Г.Т. //
Фармакоэкономика: Теория и практика. – 2014. – Т. 2, № 4. – С. 33-38 81. Ягудина, Р.И. Определение «порога общества платить» в России, в
Европейских странах и в странах СНГ / Р.И. Ягудина, А.Ю. Куликов, Т. Нгуен
// Фармакоэкономика. – 2011. – Т. 4, № 1. – C.7-12.
82. Agodi, A. Appropriate perioperative antibiotic prophylaxis: challenges, strategies, and quality indicators / A. Agodi, M. Barchitta, A. Maugeri // Epidemiol. Prev. –
2015. – Vol. 39, № 4, Suppl. 1. – P. 27-32.
83. Allegranzi, B. Impact of antibiotic changes in empirical therapy on antimicrobial resistance in intensive care unit-acquired infections / B. Allegranzi, R. Luzzati, A.
Luzzani // J. Hosp. Infect. – 2002. – Vol. 52. – P. 136-140.
84. Almeida, N.D. A Framework for Aiding the Translation of Scientific Evidence into
Policy: The Experience of a Hospital-Based Technology Assessment Unit / N.D.
Almeida, L. Mines, I. Nicolau // Int. J. Technol. Assess. Health Care. – 2019. – Vol.
35, № 3. – P. 204-211.
85. Angevine, P.D. Health economic studies: an introduction to cost-benefit, cost- effectiveness, and cost-utility analyses / P.D. Angevine, S. Berven // Spine. – 2014.
– Vol. 39, № 22, Suppl. 1. – P. 9-15.
86. Ansari, F. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis / F. Ansari, K. Gray, D.
Nathwani // J. Antimicrob. Chemother. – 2003. – Vol. 52. – P. 842-848.
87. Antimicrobial consumption in the EU/EEA. Annual epidemiological report for 2018
[Электронный ресурс].

Режим доступа: https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial- consumption-EU-EEA.pdf.


254

88. Arcieri, G.M. Safety of intravenous ciprofloxacin. A review / G.M. Arcieri, N.
Becker, B. Esposito / Am. J. Med. – 1989. – Vol. 87, № 5А. – Р. 92S-97S.
89. Arda, B. Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance /
B. Arda, O.R. Sipahi, T. Yamazhan // J. Infect. – 2007. – Vol. 55, № 1. – P. 41-48.
90. Arepyeva, M.A. A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption / M.A. Arepyeva, A.S. Kolbin, S.V. Sidorenko
// J. Glob. Antimicrob. Resist. – 2017. – Vol. 8. – P. 148-156.
91. Arnold, F.W. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: community-acquired pneumonia organization international cohort study results / F.W. Arnold, A.S. LaJoie, G.N.
Brock // Arch. Intern. Med. – 2009. – Vol. 169, № 16. – P.1515-1524.
92. Asadi, L. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis / L. Asadi,
W.I. Sligl, D.T. Eurich // Clin. Infect. Dis. – 2012. – Vol. 55, № 3. – P. 371-380.
93. Attieh, R. Implementation of local/hospital-based health technology assessment initiatives in low- and middle income countries / R. Attieh, M.P. Gagnon // Int. J.
Technol. Assess. Health Care. – 2012. – Vol. 28, № 4. – P. 445-451.
94. Babini, G.S. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997–1998 / G.S. Babini,
D.M. Livermore // J. Antimicrob. Chemother. – 2000. – Vol. 45. – P. 183-189.
95. Bailly, P. Multicentre study on the appropriateness of surgical antibiotic prophylaxis
/ P. Bailly, S. Lallemand, M.J. Thouverez // Hosp. Infect. - 2001. – Vol. 49, № 2. –
P. 135-138.
96. Banken, R. Health impact assessment – how to start the process and make it last / R.
Banken // Bill. World Health. Organ. – 2003. – Vol. 81, № 6. – P. 389.


255

97. Bantar, C. A hospital wide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance / C. Bantar, B. Sartori, E. Vesco // Clin. Infect. Dis. – 2003. –
Vol. 37. – P. 180-186.
98. Bao, L. Significant Reduction of Antibiotic Consumption and Patients’ Costs after an Action Plan in China, 2010–2014 [Электронный ресурс] / L. Bao, R. Peng, Y.
Wang // PLoS ONE. – 2015. – Vol. 10, № 3. – P. e0118868. – Режим доступа: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118868.
99. Barnett, A.G. The time-dependent bias and its effect on extra length of stay due to nosocomial infection / A.G. Barnett, J. Beyersmann, A. Allignol // Value Health. –
2011. – Vol. 14. – P. 381-386.
100. Bartlett, J.G. Community-acquired pneumonia / J.G. Bartlett, L.M. Mundy // N.
Engl. J. Med. – 1995. – Vol. 333, № 24. – P. 1618-1624.
101. Berger, M.L. Health care cost, quality and outcomes. ISPOR book of terms / M.L.
Berger. - Lawrenceville, NJ: ISPOR, 2003.
102. Berrington, A. Antimicrobial prescribing in hospitals: be careful what you measure
/ A. Berrington // J. Antimicrob. Chemother. – 2010. – Vol. 65. – P. 163-168.
103. Blackhouse, G. A Cost-Effectiveness Model Comparing Endovascular Repair to
Open Surgical Repair of Abdominal Aortic Aneurysms in Canada / G. Blackhouse,
R. Hopkins, J.M. Bowen // Value Health. – 2009. – Vol. 12, № 2. – Р. 245-252.
104. Blomberg, B. High rate of fatal cases of pediatric septicemia caused by gram- negative bacteria with extended-spectrum beta-lactamases in Dar Es Salaam,
Tanzania / B. Blomberg, R. Jureen, K.P. Manji // J. Clin. Microbiol. – 2005. – Vol.
43. – P. 745.
105. Blossom, D.B. The challenges posed by reemerging Clostridium difficile infection
/ D.B. Blossom, L.C. McDonald // Clin. Infect. Dis. – 2007. – Vol. 45. – P. 222-227.
106. Bodeau-Livinec, F. Impact of CEDIT recommendations: an example of health technology assessment in a hospital network / F. Bodeau-Livinec, E. Simon, C.


256

Montagnier-Petrissans // Int. J. Technol. Assess. Health Care. – 2006. – Vol. 22, № 2. – P. 161-168.
107. Bodro, M. Risk factors and outcomes of bacteremia caused by drug-resistant
ESKAPE pathogens in solid-organ transplant recipients / M. Bodro, N. Sabe, F.
Tubau // Transplantation. – 2013. – Vol. 96. – P. 843-849.
108. Bodrogi, J. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development / J. Bodrogi, Z. Kaló // BJP.
– 2010. – Vol. 159. – P. 1367-1373.
109. Bohnen, J.M.A. Guidelines for clinical care: anti-infective agents for intraabdominal infection. A Surgical Infection Society policy statement. / J.M.A.
Bohnen, J.S. Solomkin, E.P. Dellinger // Arch. Surg. – 1992. – Vol. 127. – P. 83-89.
110. Boyd, C.M. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance / C.M. Boyd, J.
Darer, C. Boult // JAMA. – 2005. – Vol. 294. – P. 716-724.
111. Branch-Elliman, W. Health and Economic Burden of Post-Partum Staphylococcus aureus Breast Abscess [Электронный ресурс] / W. Branch-Elliman, G.M. Lee, T.H.
Golen // PLoS One. – 2013. – Vol. 8. – P. 1-7. – Режим доступа: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0073155 112. Brown, K.A. Meta-analysis of antibiotics and the risk of community-associated
Clostridium difficile infection / K.A. Brown, N. Khanafer, N. Daneman //
Antimicrob. Agents Chemother. – 2013. – Vol. 57, № 5. – P. 2326-2332.
113. Bugnon-Reber, A. Antibiotic misuse in medium-sized Swiss hospitals / A.
Bugnon-Reber, A. de Torrenté, N. Troillet // Swiss Med. Wkly. – 2004. – Vol. 134,
№ 33-34. – P. 481-485.
114. Byford, S. Economic note: cost of illness studies / S. Byford, D.J. Torgerson, J.
Raftery // BMJ. – 2000. - Vol. 320, № 7245. – P. 1335.
115. Canadian Agency for Drugs and Technologies in Heath. HTA in hospitals
[Электронный ресурс].

CADTH,
2010.

Режим доступа:
https://www.cadth.ca/sites/default/files/pdf/hta_htupdate_issue-13_e.pdf.


257

116. Carignan, A. Risk of Clostridium difficile Infection after Perioperative
Antibacterial Prophylaxis before and during an Outbreak of Infection due to a
Hypervirulent Strain / A. Carignan, C. Allard, J. Pe´pin // Clin. Infect. Dis. – 2008. –
Vol. 46. – P. 1838-1843.
117. Castella, A. Surgical site infection surveillance: analysis of adherence to recommendations for routine infection control practices / A. Castella, L. Charrier, V.
Di Legami // Infect. Control Hosp. Epidemiol. – 2006. – Vol. 27. – P. 835-840.
118. Catananti, C. Hospital-based health technology assessment: the experience of
Agostino Gemelli University Hospital’s HTA unit / C. Catananti, A. Cicchetti, M.
Marchetti // Ital. J. Public. Health. – 2011. – Vol. 2, № 2. – P. 23-28.
119. Cheng, D. Evidence-based practice and health technology assessment: a call for anesthesiologists to engage in knowledge translation / D. Cheng, J. Martin // Can. J.
Anaesth. – 2011. – Vol. 58, № 4. – P. 354–363.
120. Cicchetti, A. Hospital based health technology assessment world-wide survey
[Электронный ресурс]. – HTAi, 2008. – Режим доступа: http://www. gisapitalia.it/nl/072011/pdf/1.pdf.
121. Cicchetti, A. Toward a contingency model for hospital-based health technology assessment: evidence from ADHOPHTA project /
A. Cicchetti, V. Iacopino, S. Coretti
// Int. J. Technol. Assess. Health Care. – 2018. – Vol. 34, № 2. – Р. 205-211.
122. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and
Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and
Society for Healthcare Epidemiology of America (SHEA) [Электронный документ].

Режим доступа: https://www.idsociety.org/practice- guideline/clostridium-difficile/.
123. Cohen, F.L. Microbial resistance to drug therapy: a review / F.L. Cohen, D.
Tartasky // Am. J. Infect. Control. – 1997. – Vol. 25. – P. 51-64.
124. Colicchio, T.K. Health information technology adoption: Understanding research protocols and outcome measurements for IT interventions in health care /
T.K.


258

Colicchio, J.C. Facelli, G. Del Fiol // J. Biomed. Inform. – 2016. – Vol. 63. – P. 33-
44.
125. Corsonello, A. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly / A. Corsonello, A.M. Abbatecola, S. Fusco // Clin. Microbiol.
Infect. – 2015. – Vol. 21, № 1. – P. 20-26.
126. Cosgrove, S.E. The impact of antimicrobial resistance on health and economic outcomes / S.E. Cosgrove, Y. Carmeli // Clin. Infect. Dis. – 2003. – Vol. 36. – P.
1433-1437.
127. Cosgrove, S.E. The relationship between antimicrobial resistance and patients outcomes: mortality, length of hospital stay, and health care cost / S.E. Cosgrove //
Clin. Infect. Dis. – 2006. – Vol. 42. – P. 82-89.
128. Culver, D.H. Surgical wound infection rates by wound class, operative procedure, and patient risk index / D.H. Culver, T.C. Horan, R.P. Gaynes // Am. J. Med. - 1991.
– Vol. 91, Suppl. 3B. – P. 152S-157S.
129. Dalgic, N. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children / N. Dalgic, M.
Sancar, B. Bayraktar // Scand. J. Infect. Dis. – 2011. – Vol. 43, № 5. – P. 339-343.
130. Daneman, N. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study / N. Daneman, H. Lu, D. Redelmeier // BMJ. - 2015. – Vol.
5. – P. 1-9.
131. De Chiara, S. Prolongation of antibiotic prophylaxis after clean and clean- contaminated surgery and surgical site infection / S. De Chiara // Minerva
Anestesiologica. – 2006. – Vol. 76, № 6. – Р. 413-419.
132. de Kraker, M.E. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant
Staphylococcus aureus bloodstream infections / M.E. de Kraker, M. Wolkewitz, P.G.
Davey // Antimicrob. Agents Chemother. – 2011. – Vol. 55. – P. 1598–1605.
133. de Lastours, V. Urinary tract infection in diabetes: epidemiologic considerations /
V. de Lastours, B. Foxman // Curr. Infect. Dis. Rep. – 2014. – Vol. 16, № 4. – Р. 389-
396.


259

134. de Lissovoy, G. Surgical site infection: incidence and impact on hospital utilization and treatment costs / G. de Lissovoy // Am. J. Infect. Control. – 2009. – Vol. 37, № 5. – P. 387-397.
135. Dean, N.C. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline / N.C. Dean, K.A. Bateman, S.M. Donnelly // Chest. – 2006. –
Vol. 130, № 3. – P. 794–799.
136. Delgado-Rodríguez, M. Epidemiology of surgical-site infections diagnosed after hospital discharge: a prospective cohort study / M. Delgado-Rodríguez, A. Gómez-
Ortega, M. Sillero-Arenas // Infect. Control. Hosp. Epidemiol. – 2001. – Vol. 22. –
P. 24-30.
137. Dellit, T.H. Infectious Diseases Society of America and the Society for Healthcare
Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship / T.H. Dellit, R.C. Owens, J.E.Jr. McGowan //
Clin. Infect. Dis. – 2007. – Vol. 44. – P.159-177.
138. Demirdjian, G. A 10-year hospital-based health technology assessment program in a public hospital in Argentina / G. Demirdjian // Int. J. Technol. Assess. Health Care.
– 2015. – Vol. 31, № 1-2. – P. 103-110. doi: 10.1017/S0266462315000124.
139. Dinubile, M.J. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy / M.J. Dinubile, I.
Friedland, C.Y. Chan // Eur. J. Clin. Microbiol. Infect. Dis. – 2005. – Vol. 24. – P.
443-449.
140. Dresser, L.D. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia / L.D. Dresser, M.S. Niederman,
J.A. Paladino // Chest. – 2001. – Vol. 119. – P. 1439–1448.
141. Drummond, M.F. Basic types of economic evaluation / M.F. Drummond, B.J.
O’Brien, G.L. Stoddart // Methods for the Economic Evaluation of Health Care
Programmes. New York: Oxford University Press, 1997. – 464 p.


260

142. Drummond, M. Assessing the Added Value of Health Technologies: Reconciling
Different Perspectives / M. Drummond, R. Tarricone, A. Torbica // Value Health. –
2013. – Vol. 16. – P. 7-13.
143. Dubberke, E.R. Burden of Clostridium difficile on the healthcare system /
E.R.
Dubberke, M.A. Olsen // Clin. Infect. Dis. – 2012. – Vol. 55, Suppl 2. – P. S88-S92.
144. Dutot, C. Hospital-based health technology assessment for the adoption of innovative medical devices within French hospitals: opportunities and challenges for industry / C. Dutot, G. Mercier, I. Borget // Int. J. Technol. Assess. Health Care. –
2017. – Vol. 33, № 2. – P.297-302.
145. Ehlers, L. Doing mini-health technology assessments in hospitals: a new concept of decision support in health care? / L. Ehlers, M. Vestergaard, K. Kidholm // Int. J.
Technol. Assess. Health Care. – 2006. – Vol. 22, № 3. – P. 295-301.
146. Eliopoulos, G.M. The impact of antibacterial resistance on health and economic outcomes / G.M. Eliopoulos, S.E. Cosgrove, Y. Carmeli // Clin. Infect. Dis. – 2003.
– Vol. 36. – P. 1433-1437.
147. Etminan, M. Oral fluoroquinolones and the risk of retinal detachment / M.
Etminan, F. Forooghian, J.M. Brophy // JAMA. – 2012. – T.4, Vol. 307, № 13. – P.
1414-1419.
148. European Network for Health Technology Assessment. EUnetHTA handbook on
HTA capacity building [Электронный ресурс]. – Barcelona: Catalan Agency for
Health Technology Assessment and Research, 2008. – Режим доступа: http://www.inahta.org/wp- content/themes/inahta/img/eunethta_wp8_hb_hta_capacity_building1.pdf
149. Fang, F.C. Point-counterpoint: what is the optimal approach for detection of
Clostridium difficile infection? / F.C. Fang, C.R. Polage, M.H. Wilcox // J. Clin.
Microbiol. – 2017. – Vol. 55. – P. 670-680.


261

150. Favaretti, C. Health technology assessment in Italy / C. Favaretti, A. Cicchetti, G.
Guarrera // Int. J. Technol. Assess. Health Care. – 2009. – № 25, Suppl. 1. – Р. 127–
133.
151. Fekety, R. Guidelines for the diagnosis and management of Clostridium difficile–
associated diarrhea and colitis. American College of Gastroenterology, Practice
Parameters Committee / R. Fekety // Am. J. Gastroenterol. – 1997. – Vol. 92. – P.
739-750.

152. Ferrer, M. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia / M. Ferrer, R. Menendez, R. Amaro // Clin. Chest.
Med. – 2011. – Vol. 32, № 3. – P. 491–505.
153. Field, T.S. Risk factors for adverse drug events among nursing home residents /
T.S. Field, J.H. Gurwitz, J. Avorn // Arch. Intern. Med. – 2001. – Vol. 161. – P. 1629-
1634.
154. Fihn, S.D. Clinical practice. Acute uncomplicated urinary tract infection in women
/ S.D. Fihn // N. Engl. J. Med. – 2003. – Vol. 349, № 3. – Р. 259-266.
155. Foglia, E. Technology assessment in hospitals: lessons learned from an empirical experiment / E. Foglia, E. Lettieri, L. Ferrario // Int. J. Technol. Assess. Health Care.
– 2017. – Vol. 33, № 2. – P. 288-296.
156. Forrest, A. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients / A. Forrest, D.E. Nix, C.H. Ballow // Antimicrob. Agents Chemother. –
1993. – Vol. 37. – P. 1073-1081.
157. Fridkin, S. Vital signs: improving antibiotic use among hospitalized patients / S.
Fridkin, J. Baggs, R. Fagan // MMWR Morb. Mortal. Wkly Rep. – 2014. – Vol. 63,
№ 9. – Р. 194-200.
158. Friedman, N.D.
The negative impact of antibiotic resistance /
N.D. Friedman, E.
Temkin, Y. Carmeli //
Clin. Microbiol. Infect. – 2016. – Vol. 22, № 5. – P. 416-422.
159. Friedrich, L.V. Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma / L.V. Friedrich, R.L. White, M.B. Kays // Am. J. Hosp. Pharm. –
1992. – Vol. 49. – P. 590-594.


262

160. Gagnon, M.P. Opportunities to promote efficiency in hospital decision-making through the use of health technology assessment [Электронный ресурс] / M.P.
Gagnon, A.B. Abdeljelil, M. Desmartis // Canadian Health Services Research
Foundation. – Ottawa, 2011. – Режим доступа: https://www.cfhi-fcass.ca/sf- docs/default-source/commissioned-research-reports/Gagnon-Dec2011-
EN.pdf?sfvrsn=0.
161. Gagnon, M. Hospital-Based Health Technology Assessment: Developments to
Date / M. Gagnon // PharmacoEconomics. – 2014. – № 32. – P. 819-824.
162. Gallagher, G. Worldwide antimicrobial susceptibility patterns among E. coli isolated from intra-abdominal infections (IAI): results from SMART 2005 / G.
Gallagher, P.R. Hsueh, F. Baquero // Surg. Infect. – 2009. – Vol. 10, № 2. – P. 99-
104.
163. Gallego, G. Resource allocation and health technology assessment in Australia: views from the local level / G. Gallego, K. van Gool, D. Kelleher // Int. J. Technol.
Assess. Health Care. – 2009. – Vol. 25, № 2. – P. 134-140.
164. Garrison, L.P. Using real-world data for coverage and payment decisions: the
ISPOR Real-World Data Task Force Report / L.P. Garrison, P.J. Neumann, P.
Erickson // Value Health. – 2007. – Vol. 10. – P. 326-335.
165. Gelband, H. State of the World's Antibiotics, 2015 / H. Gelband, M. Millen-Petrie,
S. Pant. – Washington, DC: Center for Disease Dynamics, Economics & Policy,
2015.

Электронный доступ: https://cddep.org/wp- content/uploads/2017/06/swa_edits_9.16.pdf
166. Girmenia, C. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy / C. Girmenia, G.M.
Rossolini, A. Piciocchi // Bone Marrow Transplant. – 2015. – Vol. 50. – P. 282–288.
167. Gold, M.R. Cost-effectiveness in Health and Medicine. – New York: Oxford
University Press, 1996. – 425 p.


263

168. Goldmann, D.A. Strategies to prevent and control the emergence and spread of antimicrobial- resistant microorganisms in hospitals. A challenge to hospital leadership / D.A. Goldmann, R.A. Weinstein, R.P. Wenzel // JAMA. – 1996. – Vol.
275. – P. 234-240.
169. Gomon, J. Economic assessment of effectiveness and safety of common practice perioperative antibiotic prophylaxis in a multidisciplinary hospital / J. Gomon, A.
Kolbin // Value Health. – 2018. - Vol. 21. – P. S230.
170. Gomon, J. Pharmacoeconomics modes of antibiotic therapy of uncomplicated community-acquired acute pyelonephritis in a multidisciplinary hospitals / J. Gomon,
A. Kolbin // Value Health. – 2018. - Vol. 21. – P. S477.
171. Gomon, J. The structure of consumption of antimicrobial drug for systemic use in multidisciplinary hospitals in St.Petersburg in 2014 – 2015 / J. Gomon, A. Kolbin, A.
Kurylev // Value Health. – 2018. - Vol. 21. – P. S168.
172. Gonzales, R. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians / R. Gonzales, J.F. Steiner,
M.A. Sande // JAMA. – 1997. – Vol. 278. – P. 901-904.
173. Gonzalez, C. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms / C.
Gonzalez, M. Rubio, J. Romero-Vivas // Clin. Infect. Dis. – 1999. – Vol. 29. – P.
1171–1177.
174. Grenon, X. Hospital-based health technology assessment (HB-HTA): A 10-year survey at one unit /
X. Grenon, C. Pinget, J.B. Wasserfallen // Int. J. Technol. Assess.
Health Care. – 2016. – Vol. 32, № 3. – Р. 116-121.
175. Grossman, R.F. Cost-effective therapy for acute exacerbations of chronic bronchitis / R.F. Grossman // Semin. Respir. Infect. – 2000. – Vol. 15. – P. 71–81.
176. Grossman, R.F. The value of antibiotics and the outcomes of antibiotic therapy in exacerbations of COPD / R.F. Grossman // Chest. – 1998. – Vol. 113. – P. 249S–
255S.


264

177. Guilbart, M. Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study / M. Guilbart // Br. J. Anaesth. – 2016. – Vol. 117, № 1. – P. 66–72.
178. Halmesmäki, E. Hospital-based health technology assessment (HTA) in Finland: a case study on collaboration between hospitals and the national HTA unit / E.
Halmesmäki, I. Pasternack, R. Roine // Health. Res. Policy Syst. – 2016. - № 14. – P.
25.
179. Hanberger, H. High incidence of antibiotic resistance among bacteria in four intensive care units at a university hospital in Sweden / H. Hanberger, M. Hoffmann,
S. Lindgren // Scand. J. Infect. Dis. – 1997. – Vol. 29. – P. 607-614.
180. Haug, J.B. Hospital- and patient-related factors associated with differences in hospital antibiotic use: analysis of national surveillance results / J.B. Haug, D. Berild,
M. Walberg // Antimicrob. Resist. Infect. Control. – 2014. – Vol. 3, № 1. – P. 40-50.
181. Haug, J.B. WHO defined daily doses versus hospital-adjusted defined daily doses: impact on results of antibiotic use surveillance / J.B. Haug, A. Reikvam // J.
Antimicrob. Chemother. – 2013. – Vol. 68, № 12. – P. 2940-2947.
182. Heimann, S.M. Economic burden and cost-effective management of Clostridium difficile infections / S.M. Heimann, M.R. Cruz Aguilar, S. Mellinghof // Med. Mal.
Infect. – 2018. – Vol. 48, № 1. – P. 23-29.
183. Heineck, I. Pescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil / I. Heineck, M.B. Ferreira, E.P.
Schenkel // Am. J. Infect. Control. – 1999. – Vol. 27. – P. 296-300.
184. Herring, A.R. Principles of antimicrobial use in older adults / A.R. Herring, J.C.
Williamson // Clin. Geriatr. Med. – 2007. – Vol. 23. – P. 481-497.
185. High level pharmaceutical forum 2005-2008. Conclusions and recommendations
[Электронный ресурс].

2005.

Режим доступа: http://ec.europa.eu/pharmaforum/docs/final_conclusi ons_en.pdf
186. Hirsch, E.F. “The Treatment of Infected Wounds”, Alexis Carrel's contribution to the care of wounded soldiers during World War I /
E.F. Hirsch // J. Trauma. – 2008.
– Vol. 64, Suppl 3. – P. S209-210.


265

187. Hlatky, M.A. Cost-effectiveness as an outcome in randomized clinical trials / M.A.
Hlatky, D.K. Owens, G.D. Sanders // Clin. Trials. – 2006. – Vol. 3. – P. 543-551.
188. Hopkins, J.A. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection / J.A. Hopkins, J.C. Lee, S.E. Wilson // Am. Surg. – 1993.
– Vol. 59. – P. 791-796.
189. Hosoglu, S. A national survey of surgical antibiotic prophylaxis in Turkey / S.
Hosoglu, M. Sunbul, S. Erol // Infect. Control. Hosp. Epidemiol. – 2003. – Vol. 24.
– P. 758-761.
190. Howard, D. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention – Emory workshop / D. Howard, R. Cordell, J.E. McGowan // Clin. Infect. Dis. – 2001. – Vol.
33. – P. 1573-1578.
191. Jae, H.J. Empirical Use of Ciprofloxacin for Acute Uncomplicated Pyelonephritis
Caused by Escherichia coli in Communities Where the Prevalence of
Fluoroquinolone Resistance Is High / H.J. Jae, K. Kyuseok, D.H. Woong //
Antimicrob. Agents Chemother. – 2012. – Vol. 56, № 6. – P. 3043-3046.
192. John, J.F. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital / J.F. John, N.O. Fishman // Clin. Infect. Dis. –
1997. – Vol. 24. – P. 471-485.
193. Jonsson, E. History of health technology assessment in Sweden / E. Jonsson // Int.
J. Technol. Assess. Health Care. – 2009. – Vol. 25, Suppl. 1. – P. 42-52.
194. Kaplan, W. Priority Medicines for Europe and the World / W. Kaplan, R. Laing //
Geneva: World Health Organization, 2004. – 134 p.
195. Kahveci, R. Health technology assessment in Turkey / R. Kahveci, E.M. Koç, E.Ö.
Küçük // Int. J. Technol. Assess. Health Care. – 2017. – Vol. 33, № 3. – P. 402-408.
196. Kayange, N. Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania / N. Kayange, E.
Kamugisha, D.L. Mwizamholya // BMC. – Pediatr. – 2010. – Vol. 10. – P. 39-47.


266

197. Khan, E. Increased isolation of ESBL producing Klebsiella pneumoniae with emergence of carbapenem resistant isolates in Pakistan: report from a tertiary care hospital / E. Khan, M. Ejaz, A. Zafar // J. Pak. Med. Assoc. – 2010. – Vol. 60. – P.
186-190.
198. Kleijnen, S. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions / S. Kleijnen, E. George, S. Goulden // Value Health.
– 2012. – Vol. 15, № 6. – Р. 954-960.
199. Klevens, R.M. Estimating health care-associated infections and deaths in U.S. hospitals, 2002 / R.M. Klevens // Public Health Rep. – 2007. – Vol. 122, №2. – P.
160-166.
200. Kwon, J.H. The morbidity, mortality, and costs associated with Clostridium difficile infection / J.H. Kwon, M.A. Olsen, E.R. Dubberke // Infect. Dis. Clin. North
Am. – 2015. – Vol. 29. – P.123-134.
201. Kolbin, A. Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial therapeutic agents proposed for inclusion in the essential drug list
(Russia) in 2014-2016 / А. Kolbin, Y. Gomon // Value Health. – 2017. – Vol. 20. –
P. A731.
202. Kollef, M.H. Antibiotic resistance in the intensive care unit / M.H. Kollef, V.J.
Fraser // Ann. Intern. Med. – 2001. – Vol. 134. – P. 298-314.
203. Kosherbayeva, L. Implementation of health technology assessment work in a hospital in Kazakhstan / L. Kosherbayeva, D. Hailey, K. Kurakbaev // Int. J. Technol.
Assess. Health Care. – 2016. – Vol. 32, № 1-2. – P. 78-80.
204. Kreisel, D. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity / D. Kreisel, T.G. Savel, A.L. Silver // Arch. Surg. – 1995. – Vol. 130. – P.
989–993.
205. Kuster, S.P. Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting / S.P. Kuster, C.
Ruef, B. Ledergerber // Infection. – 2008. – Vol. 36. – P. 549-559.


267

206. Kyne, L. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile / L. Kyne, M.B. Hamel, R. Polavaram. – Clin. Infect. Dis. –
2002. – Vol. 34. – P. 346-353.
207. Lambert, M.L. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study / M.L. Lambert, C. Suetens, A. Savey // Lancet Infect. Dis. – 2011. –
Vol. 11. – P. 30-38.
208. Larg, A. Cost-of-illness studies: a guide to critical evaluation / A. Larg, J.R. Moss
// Pharmacoeconomics. – 2011. – Vol. 29, № 8. – P. 653-671.
209. Laxminarayan, R. Antibiotic resistance-the need for global solutions / R.
Laxminarayan, A. Duse, C. Wattal // Lancet Infect. Dis. – 2013. – Vol. 13. – P. 1057-
1098.
210. Laxminarayan, R. Communicating trends in resistance using a drug resistance index [Электронный ресурс] / R. Laxminarayan, K.P. Klugman // BMJ Open. –
2011. Режим доступа: https://bmjopen.bmj.com/content/1/2/e000135.lon

211. Laxminarayan, R. Economics of antibiotic resistance: a theory of optimal use / R.
Laxminarayan, G.M. Brown // J. Environ. Econ. Manage. – 2001. – Vol. 42. – P.
183–206.
212. Le Doare, K. Systematic review of antibiotic resistance rates among gram-negative bacteria in children with sepsis in resource-limited countries / K. Le Doare, J.
Bielicki, P.T. Heath // J. Pediatr. Infect. Dis. Soc. – 2015. – Vol. 4, № 1. – P. 11-20.
213. Lee, S. Impact of extended-spectrum beta-lactamase on acute pyelonephritis treated with empirical ceftriaxone / S. Lee, D.Y. Song, S.H. Cho // Microb. Drug
Resist. – 2014. – Vol. 20, № 1. – P. 39-44.
214. Leistner, R. Bloodstream infection due to extended-spectrum beta-lactamase
(ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort / R. Leistner, S. Gürntke, C. Sakellariou // Infection. – 2014. – Vol. 42.
– P. 991-997.
215. Lim, P.P. Cefepime-associated thrombocytopenia in a critically ill patient / P.P.
Lim, C.P. Chong, N.A. Aziz // Int. J. Clin. Pharm. – 2011. – Vol. 33. – P. 902-904.


268

216. Lindenauer, P.K. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia / P.K. Lindenauer, S.L.
Normand, E.E. Drye // J. Hosp. Med. – 2011. – Vol. 6, № 3. – P. 142-150.
217. Lindenauer, P.K. The performance of US hospitals as reflected in risk- standardized 30-daymortality and readmission rates for medicare beneficiaries with pneumonia / P.K. Lindenauer, S.M. Bernheim, J.N. Grady // J. Hosp. Med. – 2010. –
Vol. 5, № 6. – P. E12-E18.
218. Loo, V.G. A predominantly clonal multiinstitutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality / V.G. Loo, L. Poirier,
M.A. Miller // N. Engl. J. Med. – 2005. – Vol. 353. – P. 2442–2449.
219. Macfarlane, J. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: Implications for developing management guidelines / J. Macfarlane, S.A. Lewis, R. Macfarlane //
Respir. Med. – 1997. – Vol. 91. – P. 427-434.
220. Macgowan, A. Clinical implications of antimicrobial resistance for therapy / A.
Macgowan // J. Antimicrob. Chemother. – 2008. – Vol. 62, Suppl. 2. – P. ii105-ii114.
221. Magee, G. Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011 / G. Magee, M.E. Strauss, S.M. Thomas // Am. J. Infect.
Control. – 2015. – Vol. 43, № 11. – P. 1148-1153.
222. Makady, А. Policies for Use of Real-World Data in Health Technology
Assessment (HTA): A Comparative Study of Six HTA Agencies // A. Makady, R.
Ham, A. Boer // Value Health. – 2017. – Vol. 20. – P. 520-532.
223. Maragakis, L.L. Clinical and economic burden of antimicrobial resistance / L.L.
Maragakis, E.N. Perencevich, S.E. Cosgrove // Expert. Rev. Anti Infect. Ther. –
2008. – Vol. 6. – P. 751-763.
224. Martelli, F. Health technology assessment agencies: an international overview of organizational aspects / F. Martelli, G. La Torre, E. Di Ghionno, E. // Int. J. Technol.
Assess. Health Care. – 2007. – № 23. – Р. 414-424.


269

225. Martelli, N. Hospital-based health technology assessment for innovative medical devices in university hospitals and the role of hospital pharmacists: learning from international experience / N. Martelli, A.S. Lelong, P. Prognon // Int. J. Technol.
Assess. Health Care. – 2013. – Vol. 29, № 2. – P. 185-191.
226. Martelli, N. Hospital-based health technology assessment in France: how to proceed to evaluate innovative medical devices? / N. Martelli, H. van den Brink, F.
Denies // Ann. Pharm. Fr. – 2014. – Vol. 72, № 1. – P. 3-14.
227. Martelli, N. Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting / N. Martelli, P. Hansen, H. van den Brink // J. Biomed. Inform. –
2016. – Vol. 59. – P. 201-208.
228. Martin, J. Local health technology assessment in Canada: current state and next steps / J. Martin, J. Polisena, N. Denducuri, et al. // Int. J. Technol. Assess. Health
Care. – 2016. – Vol. 32, № 3. – P. 175-180.
229. McCaig, L.F. Trends in antimicrobial drug prescribing among office-based physicians in the United States / L.F. McCaig, J.M. Hughes // JAMA. – 1995. – Vol.
273, № 3. – P. 214-219.
230. McCann, S. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes / S. McCann, J.L. Byrne, M.
Rovira // Bone Marrow Transplant. – 2004. – Vol. 33. – P. 519-529.
231. McDonald, A.H. Ring avulsion injuries / A.H. McDonald, H.J. Cleland, M. Leung
// Aust. N. Z. J. Surg. – 1999. – Vol. 69. – P. 514-516.
232. McGowan, J.E. Antimicrobial resistance in hospital organisms and its relation to antibiotic use / J.E. McGowan // Infect. Dis. – 1983. – Vol. 5. – P. 1033-1048.
233. McGregor, M. What decision-makers want and what they have been getting / M.
McGregor // Value Health. – 2006. – Vol. 9, № 3. – Р. 181-185.


270

234. McGregor, M. End-user involvement in health technology assessment (HTA) development: a way to increase impact / M. McGregor, J.M. Brophy // Int. J. Technol.
Assess. Health Care. – 2005. – Vol. 21, № 2. – P. 263-267.
235. McKinnon,
P.S.
Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients / P.S. McKinnon, J.A. Paladino, M.L. Grayson // Clin. Infect. Dis. – 1997. –
Vol. 24. – P. 57-63.
236. Men, T.Y. Prevalence of multidrug-resistant gram-negative bacilli producing extended-spectrum beta-lactamases (ESBLs) and ESBL genes in solid organ transplant recipients / T.Y. Men, J.N. Wang, H. Li // Transpl. Infect. Dis. – 2013. –
Vol. 15. – P. 14-21.
237. Mendes, R.E. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011) / R.E. Mendes, M. Mendoza, K.K. Banga Singh // Antimicrob. Agents
Chemother. – 2013. – Vol. 57, № 11. – Р. 5721-5726.
238. Merkow, R.P. Underlying reasons associated with hospital readmission following surgery in the United States / R.P. Merkow, M.H. Ju, J.W. Chung // JAMA. – 2015.
– Vol. 313, № 5. – P. 483-495.
239. Miniati, R. Hospital-based expert model for health technology procurement planning in hospitals / R. Miniati, G. Cecconi, F. Frosini // Conf. Proc. IEEE Eng.
Med. Biol. Soc. – 2014. – Vol. 2014. – P. 3504-3507.
240. Miniati, R. Development of sustainable models for technology evaluation in hospital / R. Miniati, F. Frosini, G. Cecconi // Technol. Health Care. – 2014. – Vol.
22. - № 5. – P. 729-739.
241. Mohtasham, F. Hospital-based health technology assessment in Iran / F.
Mohtasham, R. Majdzadeh, E. Jamshidi // Int. J.Technol. Assess. Health Care. – 2017.
– Vol. 33, № 4. – P. 529-533.
242. Muder, R.R. Multiply antibioticresistant gram-negative bacilli in a longterm-care facility: a case control study of patient risk factors and prior antibiotic use / R.R.


271

Muder, C. Brennen, S.D. Drenning // Infect. Control Hosp. Epidemiol. – 1997. – Vol.
18. – P. 808-813.
243. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to January 1992 to June 2002 // Am. J. Infect. Control.
– 2002. – Vol. 30. – P. 458-475.
244. Naylor, N.R. Methods for estimating the burden of antimicrobial resistance: a systematic literature review protocol / N.R. Naylor, S. Sachin, K. Kavian // Syst.
Rev. – 2016. – Vol. 5. – P. 187-191.
245. Nelson, R.E. Reducing Time-dependent Bias in Estimates of the Attributable Cost of Health Care-associated Methicillin-resistant Staphylococcus aureus Infections: A
Comparison of Three Estimation Strategies / R.E. Nelson, M.H. Samore, M. Jones //
Med. Care. – 2015. – Vol. 53. – P. 827-834.
246. Newman, W. Bacterial endocarditis; an analysis of fifty-two cases / W. Newman,
J.M. Torres, J.K. Guck // Am. J. Med. – 1954. – Vol. 16, № 4. – P. 535-542.
247. Nicolau, D.P. Experience with a once-daily aminoglycoside program administered to 2184 adult patients / D.P. Nicolau, C.D. Freeman, P.P. Belliveau // Antimicrob.
Agents Chemother. – 1995. – Vol. 39, № 3. – P. 650-655.
248. Nicolau, D.P. The costs of burn care: an analysis with an emphasis on the use of parenteral antimicrobials / D.P. Nicolau, R.L. White, L.V. Friedrich // J. Burn. Care
Rehabil. – 1994. – Vol. 15. – P. 244–250.
249. Nie, W. b-Lactam/macrolide dual therapy versus b-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. / W. Nie, B. Li, Q. Xiu // J. Antimicrob. Chemother. – 2014. – Vol.
69, №6. – P. 1441-1446.
250. Nielsen, C. Health Technology Assessment: research trends and future priorities in
Europe / С. Nielsen // J. Health Serv. Res. Policy. – 2011. – Vol. 16, Suppl. 2. – P.
6-15.
251. Nimmo, W.S. Clinical Measurement in Drug Evaluation / W.S. Nimmo, G.T.
Tucker eds. – Chichester: Wiley & Sons Ltd, 1995. – 344 p.


272

252. Norrby, S.R. Lack of development of new antimicrobial drugs: a potential serious threat to public health / S.R. Norrby, C.D. Nord, R. Finch // Lancet Infect. Dis. –
2005. – Vol. 5. – P. 115-119.
253. Nunes, A.A. Evaluation and incorporation of health technologies: process and methodology adopted by a high-complexity care university / A.A. Nunes, L.M. de
Mello, L.W. Ana // Cad. Saude Publica. – 2013. – Vol. 29, Suppl. 1. – P. 179-186.
254. O’Neil, J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. World Health Organization. Global report on surveillance / J. O’Neil. –
Geneva: World Health Organization, 2014. – Режим доступа: https://amr- review.org/sites/default/files/AMR%20Review%20Paper%20-
%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%2 0nations_1.pdf.
255. O’Sullivan, A.K. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? / A.K. O’Sullivan, D. Thompson, M.F.
Drummond // Value Health. – 2005. – Vol. 8. – P. 67-79.
256. Okon, E. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports / E. Okon, C. Engell, R. van Manen // Pharmacotherapy. – 2013. – Vol. 33. –
P. 63-68.
257. Ølholm, A.M. Hospital managers need for information on health technology investments / A.M. Ølholm, K. Kidholm, M. Birk-Olsen // Int. J. Technol. Assess.
Health Care. – 2015. – Vol. 31, № 6. – P. 414-425.
258. Ormstad, S.S. Survey and discussion of existing mini-HTA system internationally
[Электронный ресурс] / S.S. Ormstad, B.F. Graff, I.N. Norderhaug // Norwegian
Institute of
Public
Health.

Oslo,
2010.

Режим доступа: https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2010/rapport_1001_mini- hta_kartlegging_og_vurdering.pdf.
259. Ou, Y. Audits of the quality of perioperative antibiotic prophylaxis in Shandong
Province, China, 2006 to 2011 / Y. Ou, B.Q. Jing, F.F. Guo // Am. J. Infect. Control.
– 2014. – Vol. 42, № 5. – P. 516-520.


273

260. Paladino, J.A. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia / J.A. Paladino, R.E. Fell // Ann.
Pharmacother. – 1994. – Vol. 28. – P. 384-389.
261. Palmer, C.S. A prospective study of the cost-utility of the multichannel cochlear implant / C.S. Palmer, J.K. Niparko, J.R. Wyatt // Arch. Otolaryngol. Head Neck
Surg. – 1999. – Vol. 125, № 11. – P. 1221-1228.
262. Park, S.H. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase- producing Escherichia coli / S.H. Park, S.M. Choi, Y.K. Chang // J. Antimicrob.
Chemother. – 2014. – Vol. 69, № 10. – P. 2848-2856.
263. Patel, G. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies / G. Patel, S. Huprikar, S.H.
Factor // Infect. Control Hosp. Epidemiol. - 2008. – Vol. 29. – P. 1099-1106.
264. Paterson, D.L. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory / D.L. Paterson, W.C. Ko, A.
Von Gottberg // J. Clin. Microbiol. – 2001. – Vol. 39. – P. 2206-2212.
265. Pechere, J.C. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis / J.C. Pechere, L. Lacey // J.
Antimicrob. Chemother. – 2000. – Vol. 45. – P. 19-24.
266. Pedone, C. Generalizability of guidelines and physicians' adherence. Case study on the sixth joint national commitee's guidelines on hypertension / C. Pedone, K.L.
Lapane // BMC Public Health. – 2003. – Vol. 3. – P. 24-34.
267. Pereira, C.C.A. Hospital-based health technology assessment in Brazil: an overview of initial experiences / C.C.A. Pereira, R.D.S. Rabello, F.T.S. Elias // Int. J.
Technol. Assess. Health Care. – 2017. – Vol. 33, № 2. – P. 227-231.
268. Phelps, C.E. Bug/drug resistance. Sometimes less is more / C.E. Phelps // Med.
Care. – 1989. – Vol. 27. – P. 194-203.


274

269. Philips, Z. Review of guidelines for good practice in decision-analytic modelling in health technology assessment / Z. Philips, L. Ginnelly, M. Sculpher // Health
Technol. Assess. – 2004. – Vol. 8, № 36. – P. 1-158.
270. Poder, T.G. Impact of health technology assessment reports on hospital decision makers – 10-year insight from a hospital unit in Sherbrooke, Canada: impact of health technology assessment on hospital decisions / T.G. Poder, C.A. Bellemare CA, S.K.
Bédard // Int. J. Technol. Assess. Health Care. – 2018. – Vol. 34, № 4. – P. 393-399.
271. Poder, T.G. Importance of contextual data in producing health technology assessment recommendations: a case study / T.G. Poder, C.A. Bellemare // Int. J.
Technol. Assess. Health Care. – 2018. – Vol. 34, № 1. – P. 63-67.
272. Projan, S.J. Why is big Pharma getting out of antibacterial drug discovery? / S.J.
Projan // Curr. Opin. Microbiol. – 2003. – Vol. 6. – P. 427-430.
273. Pujol, M. Clinical and epidemiological findings in mechanically ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia / M. Pujol, X. Corbella,
C. Pena // Eur. J. Clin. Microbiol. Infect. Dis. – 1998. – Vol. 17. – P. 622-628.
274. Qureshi, Z.P. Market withdrawal of new molecular entities approved in the United
States from 1980 to 2009 / Z.P. Qureshi, E. Seoane-Vazquez, R. Rodriguez-Monguio
// Pharmacoepidemiol. Drug. Saf. – 2011. – Vol. 20. – P. 772-777.
275. Ramsey, S. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report / S. Ramsey, R. Willke, A.
Briggs // Value Health. – 2005. – Vol. 8. – P. 521-533.
276. Rello, J. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes / J. Rello, A. Torres, M.
Ricart M // Am. J. Respir. Crit. Care Med. – 1994. – Vol. 150. – P. 1545-1549.
277. Report of the ASM task force on antibiotic resistance // Antimicrob. Agents.
Chemother. – 1995. – Suppl. 1–23.
278. Resistance to Antibiotics: The spread of superbugs. What can be done about the rising risk of antibiotic resistance? - The Economist. – 2011, April 18th.


275

279. Reuter, P. What drug policies cost: estimating government drug policy expenditures / P. Reuter // Addiction. – 2006. – Vol. 101, № 3. – P. 315-322.
280. Ritrovato, M. Decision-Oriented Health Technology Assessment: One Step
Forward in Supporting the Decision-Making Process in Hospitals / M. Ritrovato, F.C.
Faggiano, G. Tedesco // Value Health. – 2015. – Vol. 18, № 4. – P. 505-511.
281. Roca, I. The Global Threat of Antibiotic Resistance: Moving towards concerted action: summary report of a multidisciplinary meeting [Электронный ресурс]. –
Режим доступа: https://www.researchgate.net/publication/275058757_The_global_threat_of_antimi crobial_resistance_Science_for_intervention.
282. Ronald, A. The etiology of urinary tract infection: traditional and emerging pathogens / A. Ronald // Am. J. Med. – 2002. – Vol. 113, Suppl. 1A. – P. 14S-19S.
283. Rosenstein, A.H. Assessing new technology: how are other hospitals facing the challenge? / A.H. Rosenstein, M. O’Daniel, K. Geoghan // Health. Finan. Manag. –
2003. – Vol. 57, № 10. – P. 70-74.
284. Sampietro-Colom, L. The AdHopHTA handbook: a handbook of hospital-based
Health Technology Assessment (HB-HTA) [Электронный ресурс]. – Режим доступа: http://www. adhophta.eu/handbook.
285. Sartelli, M. Management of intra-abdominal infections: recommendations by the
WSES 2016 consensus conference [Электронный ресурс] / M. Sartelli. – World
Journal of
Emergency
Surgery.

Режим доступа: https://wjes.biomedcentral.com/articles/10.1186/s13017-017-0132-7.
286. Schwaber, M. Mortality and delay in effective therapy associated with extended- spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis / M. Schwaber, Y. Carmeli // J. Antimicrob. Chemother. –
2007. – Vol. 60, № 5. – P. 913-920.
287. Sculpher, M.F. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? / M.F. Sculpher, M.J. Drummond //
Pharmacoeconomics. – 2006. – Vol. 24. – P. 1087–1099.


276

288. Sganga, G. Bacterial bloodstream infections in liver transplantation: etiologic agents and antimicrobial susceptibility profiles / G. Sganga, T. Spanu, G. Bianco //
Transplant. Proc. – 2012. – Vol. 44. – P. 1973-1976.
289. Shin, J. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact / J. Shin, J. Kim, S.H. Wie // Microb. Drug Resist.
– 2012. – Vol. 18, № 2. – P. 169-175.
290. Shiroiwa, T. International survey on willing- ness-to-pay (WTP) for one additional
QALY gained: what is the threshold of cost effectiveness? / T. Shiroiwa, Y.K. Sung,
T. Fukuda // Health Econ. – 2010. – Vol. 19. – P. 422-437.
291. Smith, R. The true cost of antimicrobial resistance / R. Smith, J. Coast // BMJ. -
2013. – Vol. 346. – P. f1493.
292. Sodhi, A. Recent trends in the management of rhegmatogenous retinal detachment
/ A. Sodhi, L.S. Leung, D.V. Do // Surv. Ophthalmol. – 2008. – Vol. 53, № 1. – P.
50-67.
293. Solomkin, J.S. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the
Infectious Diseases Society of America / J.S. Solomkin, J.E. Mazuski, J.S. Bradley //
Surg. Infect. – 2010. – Vol. 11, № 1. – P. 79-109.
294. Solomkin, J.S. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial / J.S. Solomkin, A.E. Yellin, O.D. Rotstein // Ann. Surg.
– 2003. – Vol. 237. – P. 235-245.
295. Solomkin, J.S. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious diseases society of America and the Food and
Drug Administration / J.S. Solomkin, D.L. Hemsell, R. Sweet // Clin. Infect. Dis. –
1992. – Vol. 15. – P. 33-42.
296. Solomkin, J.S. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections / J.S. Solomkin, J.E. Mazuski, E.J. Baron // Clin. Infect.
Dis. – 2003. – Vol. 37. – P. 997-1005.


277

297. Song, X. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population / X. Song, J.G. Bartlett, K. Speck // Infect.
Control. Hosp. Epidemiol. – 2008. – Vol. 29. – P. 823-828.
298. Stamm, W.E. Urinary tract infections: from pathogenesis to treatment / W.E.
Stamm, T.M. Hooton, J.R. Johnson // J. Infect. Dis. – 1989. – Vol. 159. – P. 400-406.
299. Stewardson, A. Burden of bloodstream infection caused by extended-spectrum β- lactamase-producing enterobacteriaceae determined using multistate modeling at a
Swiss University Hospital and a nationwide predictive model / A. Stewardson, C.
Fankhauser, G. De Angelis // Infect. Control. Hosp. Epidemiol. – 2013. – Vol. 34. –
P. 133-143.
300. Sturkenboom, M.C. Inappropriate initial treatment of secondary intraabdominal infections leads to increased risk of clinical failure and costs / M.C. Sturkenboom,
W.G. Goettsch, G. Picelli // Br. J. Clin. Pharmacol. – 2005. – Vol. 60. – P. 438-443.
301. Suankratay, C. A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria / C.
Suankratay, K. Jutivorakool, S. Jirajariyavej // J. Med. Assoc. Thai. – 2008. – Vol.
91, № 8. – P. 1172-1181.
302. SuSMita, B. Surgical Site Infection by Methicillin Resistant Staphylococcus aureus – on Decline? / B. SuSMita // JCDR. – 2016. – Vol. 10, № 9. – P. DC32-
DC36.
303. Tacconelli, E. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis / E. Tacconelli, E. Carrara,
A. Savoldi // Lancet Infect. Dis. – 2018. – Vol. 18. – P. 318-327.
304. Tal, O. Hospital staff perspectives towards health technology assessment: data from a multidisciplinary survey / O. Tal, M. Booch, S. Bar-Yehuda // Health Res.
Policy Syst. – 2019. – Vol. 17, № 1. – P. 72.
305. Talbot, G.H. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Disease Society of America
/ G.H. Talbot, J. Bradley, J.E. Edwards // Clin. Infect. Dis. – 2006. – Vol. 42. – P.
657-668.


278

306. Teillant, A. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study / A. Teillant, S. Gandra, D. Barter // Lancet Infect. Dis. – 2015. – Vol. 15, № 12. – P. 1429-1437.
307. The bacterial challenge: time to react. ECDC/EMEA joint technical report
[Электронный ресурс].

Режим доступа: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_T
ER_The_Bacterial_Challenge_Time_to_React.pdf.
308. Thomas, J.K. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy / J.K.
Thomas, A. Forrest, S.M. Bhavnani // Antimicrob. Agents Chemother. – 1998. – Vol.
42. – P. 521-527.
309. Tillotson, G.S. Burden of antimicrobial resistance in an era of decreasing susceptibility / G.S. Tillotson, S.H. Zinner //
Expert Rev. Anti-infect. Ther. – 2017. –
Vol. 15. – P. 663-676.
310. Tomera, K.M. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study / K.M. Tomera, E.A. Burdmann, O.G.
Reyna // Antimicrob. Agents Chemother. – 2002. – Vol. 46, № 9. – P. 2895-2900.
311. Torbica, A. Does the approach to economic evaluation in health care depend on culture, values, and institutional context? / A. Torbica, R. Tarricone, M. Drummond
// Eur. J. Health Econ. - 2018. – Vol. 19, № 6. – P. 769-774.
312. Torrance, G.W. Measurement of health state utilities for economic appraisal /
G.W. Torrance // J. Health Econ. – 1986. – Vol. 5. – P. 1-30.
313. Tourmousoglou, C.E. Adherence to guidelines for antibiotic prophylaxis in general surgery: a critical appraisal / C.E. Tourmousoglou, E.Ch. Yiannakopoulou,
V.J. Kalapothaki // Antimicrob. Chemother. – 2008. – Vol. 61. – P. 214-218.
314. Tünger, O. Evaluation of rational antibiotic use / O. Tünger, G. Dinç, B.
Ozbakkaloglu // Int. J. Antimicrob. Agents. – 2000. – Vol.15, № 2. – P. 131-135.


279

315. Uematsu, H. Impact of guideline-concordant microbiological testing on outcomes of pneumonia / H. Uematsu, H. Hashimoto, T. Iwamoto // Int. J. Qual. Health Care.
– 2014. – Vol. 26, № 1. – Р. 100-107.
316. Umscheid, C.A. Hospital-based comparative effectiveness centers: translating research into practice to improve the quality, safety and value of patient care / C.A.
Umscheid, K. Williams, P.J. Brennan // J. Gen. Intern. Med. – 2010. – Vol. 25, № 12.
– P. 1352-1355.
317. Urgently needed: new antibiotics. Editorial letter [Электронный ресурс]. –
Режим доступа: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-
6736(09)62076-6.pdf.
318. Vaishnavi, C. Established and potential risk factors for Clostridum difficile infection / C. Vaishnavi // Indian J. Med. Microbiol. – 2009. – Vol. 27, № 4. – P.
289-300.
319. Van Boeckel, T.P. Global antibiotic consumption 2000 to 2010: an analysis national pharmaceuticals sales data / T.P. Van Boeckel, S. Gandra, A. Ashok //
Lancet Infect. Dis. – 2014. – Vol. 14. – P. 742-750.
320. Van Boeckel, T.P. Global trends in antimicrobial use in food animals / T.P. Van
Boeckel, C. Brower, M. Gilbert // Proc. Natl. Acad. Sci. USA. - 2015. – Vol. 112,
№ 18. – P. 5649-5654.
321. Van Delden, C. Multidrug resistant gram-negative bacteria in solid organ transplant recipients / C. Van Delden, E.A. Blumberg // Am. J. Transplant. – 2009. –
Vol. 9. – P. A27-A34.
322. Van Kasteren, M.E. Antibiotic Prophylaxis and the Risk of Surgical Site Infections following Total Hip Arthroplasty: Timely Administration Is the Most Important
Factor / M.E. Van Kasteren, J. Manniën, A. Ott // Clinical Infectious Diseases. –
2007. – Vol. 44. – P. 921-927.
323. Van Spall, H.G. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review /H.G. Van
Spall, A. Toren, A. Kiss // JAMA. – 2007. – Vol. 297. – P. 1233-1240.


280

324. Velasco Garrido, M. Health technology assessment and health policy-making in
Europe: current status, challenges and potential [Электронный ресурс]. – Режим доступа: http://www.euro.who.int/__data/assets/pdf_file/0003/90426/E91922.pdf
325. Verbeek, J. Sharing and collecting hospital-based health technology assessment reports internationally: is an extensive participation of stakeholders realistic? / J.
Verbeek, M. Hiligsmann, A. Cicchetti // Int. J. Technol. Assess. Health Care. – 2018.
- Vol. 34, № 5. – P. 527-534.
326. Viswanathan, R. Profile of neonatal septicaemia at a district-level sick newborn care unit / R. Viswanathan, A.K. Singh, C.J. Ghosh // Health Popul. Nutr. – 2012. –
Vol. 30. – P. 41-48.
327. Wagenlehner, F.M.E. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study / F.M.E. Wagenlehner,
E. Van Oostrum, P. Tenke // Eur. Urol. – 2013. – Vol. 63. – P. 521-527.
328. Walley, T. Pharmacoeconomics / T. Walley, A. Haycox, A. Boland. – Elsevier
Health Sciences, 2004. – 216 p.
329. Walters, D.J. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intraabdominal infections / D.J. Walters, J.S.
Solomkin, J.A. Paladino // Pharmacoeconomics. – 1999. – Vol. 16. – P. 551-561.
330. Wang, G.F. Metallo-beta-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design / G.F. Wang, K.C. Chou // Curr. Top. Med. Chem. –
2013. – Vol. 13. – P. 1242-1253.
331. Waters, D. Aetiology of community-acquired neonatal sepsis in low and middle income countries / D. Waters, I. Jawad, A. Ahmad // J. Glob. Health. – 2011. – Vol.
1. – P. 154-170.
332. Weinstein, M.C. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices
– Modeling Studies // M.C. Weinstein, B. O’Brien, J. Hornberger // Value Health. –
2003. – Vol. 6. – P. 9-17.


281

333. Wells, W.G. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy / W.G. Wells, G.L. Woods, Q.
Jiang // J. Antimicrob. Chemother. – 2004. – Vol. 53, Suppl. 2. – P. 67-74.
334. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index
2018
[Электронный ресурс].

Режим доступа: https://www.whocc.no/atc_ddd_index/.
335. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment [Электронный ресурс]. Режим доступа: https://www.whocc.no/filearchive/publications/guidelines.pdf.
336. WHO Global Strategy for Containment of Antimicrobial Resistance
[Электронный ресурс].

Режим доступа: http://apps.who.int/iris/bitstream/10665/66860/1/WHO_CDS_CSR_DRS_2001.2.p df?ua=1.
337. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation [Электронный ресурс]. – Geneva: World Health Organization;
2018. – Режим доступа: http://www.who.int/medicines/areas/rational_use/who- amr-amc-report-20181109.pdf?ua=1 338. WHO. Antimicrobial resistance (WHO Fact sheet). Geneva: World Health
Organization. – 2018 [Электронный ресурс]. – Режим доступа: http:// www.who.int/en/news-room/factsheets/detail/antimicrobial-resistance
339. WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis. Geneva:
World Health Organization. – 2017 [Электронный ресурс]. – Режим доступа: http:// www.who.int/medicines/areas/rational_ use/PPLreport_2017_09_19.pdf?ua=1.
340. Wie, S.H. Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli:
10-year experience / S.H. Wie, H.W. Kim, U.I. Chang / Microb. Drug. Resist. – 2013.
– Vol. 19, № 4. – P. 316-322.


282

341. Williamson, D.A. Infectious complications following transrectal ultrasound- guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli / D.A. Williamson, L.K. Barrett, B.A. Rogers // Clin. Infect. Dis. – 2013. – Vol.
57. – P. 267-274.
342. Wilton, P. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness / P. Wilton, R. Smith, J.
Coast // J. Health Serv. Res. Policy. – 2002. – Vol. 7. – P. 111-117.
343. Wise, R. The need for new antibiotics / R. Wise, L. Piddock // Lancet. – 2010. –
Vol. 375. – P. 638-642.
344. World Health Organization. Development of Country Profiles and monitoring of the pharmaceutical situation in countries: Pharmaceutical Sector Country Profiles
Data and
Reports
[Электронный ресурс].

Режим доступа: http://www.who.int/medicines/areas/coordination/coordination_assessment/en/inde x1.html.
345. World Health Organization. Global report on surveillance [Электронный ресурс].
- Geneva: World Health Organization; 2014. – Режим доступа: http://www.who.int/drugresistance/documents/surveillancereport/en/.

346. World Health Organization: The Global Burden of Disease: 2004 Update
[Электронный ресурс].

Режим доступа: http://www.who.int/healthinfo/global_burden_disease/2004_report_ update/en/index.html.
347. Yalçin, A.N. Surgical antibiotic prophylaxis in a Turkish university hospital / A.N.
Yalçin, S. Serin, E. Gurses // J. Chemother. – 2002. – Vol. 14, №4. – P. 373-377.
348. Yen, Z.S. A cost-effectiveness analysis of treatment strategies for acute uncomplicated pyelonephritis in women / Z.S. Yen, M.A. Davis, S.C. Chen // Acad.
Emerg. Med. – 2003. – Vol. 10, № 4. – P. 309-314.


Каталог: upload -> site56 -> document file


Поделитесь с Вашими друзьями:
1   ...   139   140   141   142   143   144   145   146   147


База данных защищена авторским правом ©zodorov.ru 2017
обратиться к администрации

    Главная страница